Head and Neck Cancers
If it’s your first time on this website, please read the disclaimer section.
Jul 13 – Jul 20, 2026
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3, randomized, placebo-controlled trial evaluated dabrafenib plus trametinib in 153 adults with radioactive iodine-refractory BRAF-positive differentiated thyroid cancer. The combination significantly extended progression-free survival (median 12.8 months vs 3.7 months; HR 0.38, p<0.0001) and improved overall response rate (57% vs 4%) compared to placebo. While overall survival did not reach significance in interim analysis, the safety profile showed no new signals. These findings support the second-line use of dabrafenib plus trametinib, offering a new therapeutic option for this challenging cancer population.
10.1016/S1470-2045(26)00133-6
Jun 29 – Jul 06, 2026
Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international expert consensus statement provides pragmatic guidance for reirradiation in recurrent or second primary head and neck squamous cell carcinoma (HNSCC) within previously irradiated regions, a scenario with few therapeutic options. Developed through a structured expert consensus process, it reflects current expert practice across key domains including patient selection, imaging, and toxicity management. The consensus aims to promote more consistent practice and facilitate communication across centers for this complex cancer. It offers a shared clinical framework to support clinicians in making informed choices and guide future research efforts in HNSCC reirradiation.
10.1016/S1470-2045(26)00174-9
Jun 22 – Jun 29, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The JCOG1008 randomized phase II/III trial’s long-term follow-up compared weekly versus 3-weekly cisplatin chemoradiotherapy in 261 patients with postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). At 5.6 years median follow-up, 5-year overall survival was 58.7% (3-weekly) vs. 71.2% (weekly) (HR 0.76), confirming noninferiority of the weekly regimen. Weekly cisplatin also showed numerically better 5-year relapse-free and local RFS, with no significant late adverse event differences, directly impacting cancer treatment strategies. These results support weekly cisplatin plus radiotherapy as a reasonable and effective alternative for this specific cancer patient population.
10.1200/JCO-25-01708
Jun 15 – Jun 22, 2026
Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This multicenter, randomized trial investigated becotatug vedotin, an anti-EGFR antibody-drug conjugate, against chemotherapy in 173 patients with heavily pretreated recurrent/metastatic nasopharyngeal carcinoma. Becotatug vedotin significantly improved the objective response rate (30.2% vs 11.5%; P=0.003) and progression-free survival (median 5.82 vs 2.83 months; HR 0.63; P=0.01) compared to chemotherapy. Interim overall survival was encouraging at 17.08 vs 11.99 months, with comparable safety profiles between groups. These findings suggest becotatug vedotin offers a clinically meaningful new treatment option for patients with advanced NPC who have exhausted prior therapies, directly addressing a critical need in cancer management.
10.1016/j.annonc.2026.06.003
Management of Differentiated Thyroid Cancer.
NEW ENGL J MED · Q1 JOURNAL - RANK #2/332TOP-TIER
This article presents a clinical framework for the risk-adapted management of differentiated thyroid cancer, emphasizing dynamic risk stratification from initial diagnosis through long-term follow-up. The methodology focuses on integrating clinicopathological staging with molecular risk characterization to develop and modify personalized treatment plans over time. Key findings highlight decision-making pathways for active surveillance in low-risk papillary cases, minimalist interventions for intermediate-risk patients, and systemic therapies for advanced disease. This framework provides clinicians with a structured approach to balance therapeutic benefits against risks while incorporating patient preferences into informed management recommendations.
10.1056/NEJMra2416814
Jun 08 – Jun 15, 2026
Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This prospective quality improvement study evaluated the efficacy of prompt-directed ambient artificial intelligence (AI) for documenting multidisciplinary head and neck cancer tumor board discussions compared to manual methods. Results demonstrated that prompt-directed AI significantly improved total documentation scores (p=0.005) and tumor characteristic accuracy (q=0.042) compared to unprompted AI without increasing discussion time. Compared to manual documentation, ambient AI enhanced discussion domain scores (q<0.001) and total quality (p<0.001) while significantly reducing per-patient administrative burden (p<0.001). These findings suggest that integrating directed prompting into ambient AI workflows can optimize oncology documentation quality and clinical efficiency during complex multidisciplinary decision-making.
10.1016/j.annonc.2026.05.709
Jun 01 – Jun 08, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 first-in-human trial evaluated IMA401, a TCR-based bispecific T cell engager targeting MAGE-A4/MAGE-A8, in 61 patients with recurrent or refractory solid tumors. The recommended phase 2 dose was established at 1-2 mg biweekly, with a manageable safety profile featuring 38% grade 1-2 cytokine release syndrome and no maximum tolerated dose reached. Efficacy results showed a 20% objective response rate at the recommended dose across multiple indications, notably reaching 29% in head and neck cancer patients. These findings demonstrate the clinical potential of the bispecific TCER platform as a promising immunotherapy for advanced malignancies.
10.1038/s41591-026-04455-x
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 1b/2 study evaluated amivantamab, an EGFR-MET bispecific antibody, in 102 patients with recurrent/metastatic head and neck squamous cell carcinoma after prior checkpoint inhibitor and platinum chemotherapy. The primary endpoint of objective response rate (ORR) by blinded independent review was 42% (95% CI, 32-52), including a 15% complete response rate, with a median progression-free survival of 6.8 months and overall survival of 12.5 months. These outcomes exceed the typical 21-24% ORR seen with single-agent paclitaxel or cetuximab in this refractory population, offering a novel targeted therapy option. For a clinician focused on cancer research, this provides high-level evidence for a new treatment strategy in a difficult-to-treat malignancy, though results require confirmation in larger randomized trials.
10.1200/JCO-26-01042
May 25 – Jun 01, 2026
Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This cross-sectional study used a difference-in-differences design to evaluate whether regional participation in the NHS-Galleri multicancer early detection (MCED) trial affected cancer diagnostic delay rates across 21 regions in England. In the first six months, participating regions saw diagnostic delay rates rise from 28.6% to 29.6%, while non-participating regions decreased from 28.9% to 26.3%, representing a 3.4 percentage point adjusted difference (P < .001). The study highlights that large-scale cancer screening trials can increase system-level demand, evidenced by a 4.8 percentage point increase in delays during the second six-month period and higher referral rates. Clinicians and health systems must account for these “spillover effects” on existing cancer diagnostic pathways when implementing population-based screening interventions to ensure timely care for all suspected cancer patients.
10.1001/jama.2026.6803
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This national cohort study assessed longitudinal risks and methods for suicidal self-directed violence (SSDV) among 292,271 veterans with invasive solid or hematologic cancer (2014-2023) using registries. Overall, 2400 SSDV events occurred (203 per 100,000 person-years), with poisoning most common (26%). High rates were found in patients with CNS, pancreas, head and neck, liver and biliary system, and thyroid cancers, advanced cancer (261 per 100,000 person-years), severe frailty, chronic mental illness, and high pain scores. Risks persisted five years post-diagnosis for younger (≤45 years), unmarried, advanced cancer, and CNS cancer patients, highlighting vulnerable subgroups. This emphasizes the critical need for systematic tracking of suicidal behaviors and tailored screening strategies within comprehensive cancer care, especially for these high-risk populations.
10.1001/jamaoncol.2026.1459
May 04 – May 11, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase I/Ib trial investigated ficerafusp alfa plus pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) overexpressing PD-L1, assessing safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Among 42 patients, 45% experienced grade ≥3 treatment-related adverse events. Confirmed ORRs were 54% (21% complete response) for HPV-negative (n=28) and 27% for HPV-positive (n=11) tumors. For HPV-negative patients, median PFS was 9.9 months and median OS was 21.3 months, demonstrating promising antitumor activity directly relevant to cancer treatment. This combination shows favorable safety and efficacy, particularly in HPV-negative R/M HNSCC, suggesting a potential new first-line therapeutic strategy for this challenging cancer population.
10.1200/JCO-25-02027
Apr 27 – May 04, 2026
An agentic framework for autonomous scientific discovery in cancer pathology.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This study introduces SPARK, an agentic AI framework that uses natural language to autonomously generate biologically driven analytical tools for tumor pathology without extra model training. Evaluated across 18 cohorts with over 5,400 patients spanning five cancer types, SPARK produced clinically relevant concepts correlated with prognosis, pathological variables, and predictive biomarkers, including inferred tumor progression from static images. The framework directly addresses the clinician’s interest in cancer-focused research by demonstrating applicability in lung, colorectal, breast, and oropharyngeal cancers, with evidence of prognostic and predictive value. Primary implications include potential to enhance diagnostic precision and biological insight, though prospective clinical validation is still needed before routine use.
10.1038/s41591-026-04357-y